HemaSphere
(Jun 2022)
P440: THE COMBINATION VENETOCLAX PLUS MCL1 OVERCOMES DRUG RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA
- D. A. Pereira-Martins,
- N. I. Noguera,
- T. Ottone,
- A. Diepstra,
- C. Ortiz,
- I. Weinhauser,
- G. Huls,
- J. J. Schuringa,
- E. M. Rego,
- E. Ammatuna
Affiliations
- D. A. Pereira-Martins
- 1 Center for Cell Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
- N. I. Noguera
- 3 Department of Biomedicine and Prevention, University of Tor Vergata
- T. Ottone
- 3 Department of Biomedicine and Prevention, University of Tor Vergata
- A. Diepstra
- 5 Department of Pathology and Medical Biology, Cancer Research Centre Groningen, University Medical Center Groningen, Groningen, Netherlands
- C. Ortiz
- 1 Center for Cell Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
- I. Weinhauser
- 1 Center for Cell Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
- G. Huls
- 2 Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Center Groningen, Groningen, Netherlands
- J. J. Schuringa
- 2 Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Center Groningen, Groningen, Netherlands
- E. M. Rego
- 1 Center for Cell Based Therapy, University of Sao Paulo, Ribeirao Preto, Brazil
- E. Ammatuna
- 2 Department of Experimental Hematology, Cancer Research Centre Groningen, University Medical Center Groningen, Groningen, Netherlands
- DOI
-
https://doi.org/10.1097/01.HS9.0000844648.16285.a3
- Journal volume & issue
-
Vol. 6
pp.
340
– 341
WeChat QR code